Drug
Fimasartan clinical trials
Includes 2 studies of Fimasartan potassium trihydrate.
- studies test it
- 49
- open now
- 1
- in phase 3
- 12
- first study started
- 2003
Keep track of what changes. Save the fimasartan studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Studies by the year they started
49 studies that test it; most in 2009 (7)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2004 | 1 |
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 7 |
| 2010 | 3 |
| 2011 | 1 |
| 2012 | 6 |
| 2013 | 3 |
| 2014 | 7 |
| 2015 | 6 |
| 2016 | 3 |
| 2017 | 2 |
| 2018 | 2 |
| 2019 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 23
- Phase 2
- 4
- Phase 3
- 12
- Phase 4
- 9
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 41 · Other 8
Boryung Pharmaceutical Co., Ltd (39) · Seoul National University Hospital (2) · R-Pharm (1) · Asan Medical Center (1) · Stendhal Americas, S.A. (1) · Seoul National University Bundang Hospital (1) · Seung-Jung Park (1) · Centro Universitario de Ciencias de la Salud, Mexico (1)
Often tested with
Tested in the same studies.
Amlodipine (9) · Rosuvastatin (7) · Atorvastatin (6) · Hydrochlorothiazide (3) · Indapamide (2) · Ezetimibe (1) · Candesartan cilexetil (1) · Digoxin (1)
Studies
Open first, then newest update. How each study uses fimasartan is read from its arms, and is right about nine times in ten.
Testing it · 49
- Effect of Fimasartan on Extended RAS and Vascular Functions in Patients With Type 2 Diabetes and HypertensionRecruitingPhase 4Seoul National University Bundang HospitalNCT05173025Written as Fimasartan
- A Study to Evaluate the Efficacy and Safety of BR1015 Combination TherapyCompletedPhase 3Boryung Pharmaceutical Co., LtdNCT05878561Written as Fimasartan + Indapamide
- A Study to Evaluate the Efficacy and Safety of BR1017A and BR1017B Combination Therapy in Essential Hypertension Patients With Primary HypercholesterolemiaCompletedPhase 3Boryung Pharmaceutical Co., LtdNCT05930028Written as Fimasartan
- A Clinical Trial to Evaluate Drug-drug Interactions and Safety Between "BR1015-1" and "BR1015-2" in Healthy VolunteersCompletedPhase 1Boryung Pharmaceutical Co., LtdNCT05097794Written as BR1015-1
- BR1010 in Patients With Essential Hypertension Patients Who do Not Adequately Respond to Fimasartan/Amlodipine CombinationCompletedPhase 3Boryung Pharmaceutical Co., LtdNCT03991442Written as Fimasartan/Amlodipine
- A Study to Evaluate the Efficacy and Safety of Combination Treatment of Fimasartan/Atorvastatin in Patients With Essential Hypertension and DyslipidemiaCompletedPhase 3Boryung Pharmaceutical Co., LtdNCT03338426Written as Fimasartan 120mg
- Combination of Fimasartan/Amlodipine/Rosuvastatin in Patients With Essential Hypertension and DyslipidemiaCompletedPhase 3Boryung Pharmaceutical Co., LtdNCT03156842Written as Fimasartan/Amlodipine, Rosuvastatin
- Efficacy and Safety Evaluating Study to Compare Kanarb (Fimasartan) and Cozaar® (Losartan) in Adult Patients With Grade I-II Arterial HypertensionCompletedPhase 3R-PharmNCT02248961Written as Fimasartan
- A Clinical Trial to Evaluate the Pharmacokinetics and Safety of Fimasartan and Rosuvastatin in Healthy Male SubjectsCompletedPhase 1Boryung Pharmaceutical Co., LtdNCT02704702Written as Fimasartan
- Effect of Fimasartan for Modification of Atheroma Vulnerability in DEFERred Coronary Disease (FIMA-DEFER)TerminatedPhase 4Seung-Jung ParkNCT01384747Written as Fimasartan
- Clinical Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Hypertension PatientsCompletedPhase 3Boryung Pharmaceutical Co., LtdNCT00922480Written as Fimasartan
- A Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan (BR-A-657•K) During 24 Hours in Patients With Mild to Moderate Essential HypertensionCompletedPhase 2Boryung Pharmaceutical Co., LtdNCT00922441Written as Fimasartan 60 mg group
- A Clinical Trial to Evaluate the Pharmacokinetics and Safety/Tolerability of Fimasartan and Atorvastatin in Healthy Male Volunteers.CompletedPhase 1Boryung Pharmaceutical Co., LtdNCT02994745Written as Fimasartan, Atorvastatin
- A Clinical Trial to Evaluate the Pharmacokinetics and Safety of Fimasartan and Amlodipine in Healthy Male SubjectsCompletedPhase 1Boryung Pharmaceutical Co., LtdNCT02920047Written as Fimasartan/Amlodipine
- Fimasartan Plus Amlodipine on Hemodynamic Parameters and Arterial Stiffness in Patients With HypertensionStatus unknownPhase 4Centro Universitario de Ciencias de la Salud, MexicoNCT03294070Written as Fimasartan plus amlodipine besylate
- Fimasartan Achieving SBP Target (FAST) StudyCompletedPhase 4Boryung Pharmaceutical Co., LtdNCT02495324Written as Fimasartan
- Effects of Fimasartan on Insulin Secretion in Type 2 Diabetic PatientsCompletedNot applicableSeoul National University HospitalNCT02312375Written as Fimasartan
- A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Combination of Fimasartan/Rosuvastatin in Comparison to Each Component Administered Alone in Patients With Essential Hypertension and DyslipidemiaCompletedPhase 3Boryung Pharmaceutical Co., LtdNCT02166814Written as Fimasartan and Rosuvastatin
- Comparison of Blood Pressure Lowering Effect Between Fimasartan and LosartanStatus unknownPhase 4Chuncheon Sacred Heart HospitalNCT02958631Written as Fimasartan
- Clinical Study to Evaluate the Antihypertensive Efficacy and Changes of Neurohormonal Markers of Fimasartan and Atenolol With Exaggerated Blood Pressure Response During Exercise in Essential Hypertensive PatientsCompletedPhase 4Boryung Pharmaceutical Co., LtdNCT01736488Written as Fimasartan
See all 49 studies that test fimasartan →
As the comparator · 8 — what is tested is compared with fimasartan
- A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-1 and BR1015-2 Under Fed ConditionsNot yet recruitingPhase 1Boryung Pharmaceutical Co., LtdNCT07421388Written as BR1015-1
- A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-1 and BR1015-2 Under Fasting ConditionsNot yet recruitingPhase 1Boryung Pharmaceutical Co., LtdNCT07421375Written as BR1015-1
- A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-1 and BR1015-2 Under Fasting ConditionsCompletedPhase 1Boryung Pharmaceutical Co., LtdNCT06744127Written as BR1015-1
- A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-1 and BR1015-2 in Healthy Volunteers Fed ConditionsCompletedPhase 1Boryung Pharmaceutical Co., LtdNCT06744062Written as BR1015-1
- A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fasting Conditions in Healthy VolunteersCompletedPhase 1Boryung Pharmaceutical Co., LtdNCT06008028Written as BR1015-1
- A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy VolunteersCompletedPhase 1Boryung Pharmaceutical Co., LtdNCT06008015Written as BR1015-1
- A Clinical Study to Evaluate Efficacy and Safety of Fimasartan/Hydrochlorothiazide Combination-therapyCompletedPhase 3Boryung Pharmaceutical Co., LtdNCT01258673Written as Fimasartan
- Efficacy, Safety and Pharmacodynamic/Pharmacokinetic Study of Fimasartan (BR-A-657•K)CompletedPhase 2Boryung Pharmaceutical Co., LtdNCT00937651Written as Fimasartan (BR-A-657•K) 20 mg
Codes
What other systems call fimasartan · ClinicalTrials.gg INT005848
- MeSH (NLM) C558933fimasartanOne source NLM
- UNII (FDA) P58222188PFIMASARTANConfirmed FDA, NLM, Wikidata
- Wikidata Q8563179fimasartanConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C81417FimasartanOne source FDA
- DrugBank DB09279One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C558933 | fimasartan | One source NLM |
| UNII (FDA) | P58222188P | FIMASARTAN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q8563179 | fimasartan | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C81417 | Fimasartan | One source FDA |
| DrugBank | DB09279 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.